0.64
+0.0605(+10.50%)
Currency In USD
| Previous Close | 0.58 |
| Open | 0.6 |
| Day High | 0.64 |
| Day Low | 0.59 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.31 |
| Volume | 1.34M |
| Average Volume | 7.95M |
| Market Cap | 18.75M |
| PE | -0.92 |
| EPS | -0.69 |
| Moving Average 50 Days | 0.8 |
| Moving Average 200 Days | 0.85 |
| Change | 0.06 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $53.06 as of January 05, 2026 at a share price of $0.637. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $707.44 as of January 05, 2026 at a share price of $0.637.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
GlobeNewswire Inc.
Dec 18, 2025 2:15 PM GMT
-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedi
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
GlobeNewswire Inc.
Nov 10, 2025 2:00 PM GMT
-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
GlobeNewswire Inc.
Nov 03, 2025 1:30 PM GMT
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 m